Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies

Basit Öğe Kaydı
dc.authoridOklu, Rahmi/0000-0003-4984-1778
dc.authoridCevik, Enes/0000-0002-1240-6150
dc.authoridAltun, Izzet/0000-0001-6497-9017
dc.contributor.authorAltun, Izzet
dc.contributor.authorDemirlenk, Yusuf M.
dc.contributor.authorAtar, Dila
dc.contributor.authorCevik, Enes
dc.contributor.authorGunduz, Seyda
dc.contributor.authorAlbadawi, Hassan
dc.contributor.authorOklu, Rahmi
dc.date.accessioned2024-05-19T14:50:29Z
dc.date.available2024-05-19T14:50:29Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractInterventional immuno-oncology is making strides in locoregional therapies to address complex tumor microenvironments. Long-standing interventional radiology cancer therapies, such as tumor ablation and embolization, are being recharacterized in the context of immunotherapy. Intratumoral injections, such as those of genetically engineered or unaltered viruses, and the delivery of immune cells, antibodies, proteins, or cytokines into targeted tumors, along with advancements in delivery techniques, have produced promising results in preliminary studies, indicating their antitumor effectiveness. Emerging strategies using DNA scaffolding, polysaccharides, glycan, chitosan, and natural products are also showing promise in targeted cancer therapy. The future of interventional immuno-oncology lies in personalized immunotherapies that capitalize on individual immune profiles and tumor characteristics, along with the exploration of combination therapies. This study will review various interventional immuno-oncology strategies and emerging technologies to enhance delivery of therapeutics and response to immunotherapy.en_US
dc.description.sponsorshipNational Institutes of Health [R01CA257558, R01HL140951, R01DK130566, R01HL165176, R01HL137193]; Clinician Investigator Award from Mayo Clinicen_US
dc.description.sponsorshipACKNOWLEDGMENTS R.O. gratefully acknowledges funding from the National Institutes of Health (R01CA257558, R01HL140951, R01DK130566, R01HL165176 and R01HL137193) , and the Clinician Investigator Award from Mayo Clinic.en_US
dc.identifier.doi10.1016/j.jvir.2023.10.009
dc.identifier.endpage172en_US
dc.identifier.issn1051-0443
dc.identifier.issn1535-7732
dc.identifier.issue2en_US
dc.identifier.pmid38272636en_US
dc.identifier.scopus2-s2.0-85182574644en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage164en_US
dc.identifier.urihttps://doi.org10.1016/j.jvir.2023.10.009
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5724
dc.identifier.volume35en_US
dc.identifier.wosWOS:001174835800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Vascular and Interventional Radiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectHepatocellular-Carcinomaen_US
dc.subjectIntralesional Pv-10en_US
dc.subjectCell Immunotherapyen_US
dc.subjectOncolytic Virusesen_US
dc.subjectCanceren_US
dc.subjectBlockadeen_US
dc.subjectAblationen_US
dc.subjectCryoablationen_US
dc.subjectBarriersen_US
dc.subjectDeliveryen_US
dc.titleAdvances and Challenges in Interventional Immuno-Oncology Locoregional Therapiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu